GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has scheduled the release of its second quarter 2025 financial results for July 28, 2025, after the U.S. markets close. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET, where the company's management will discuss the financial outcomes and provide a corporate update. This event is crucial for investors and stakeholders interested in the advancements of GeoVax's multi-antigen vaccines and immunotherapies targeting infectious diseases and cancer.
Interested parties can access the live conference call by registering here, with the webcast available on the GeoVax website under the Investor Relations section. Telephone participation is also an option, requiring prior registration here. The webcast will be archived on the company's website approximately two hours post-call, remaining accessible for at least 90 days.
GeoVax's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, is currently undergoing three Phase 2 clinical trials. These trials aim to evaluate its efficacy as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a durable booster for healthy individuals previously vaccinated with mRNA vaccines. Additionally, the company is advancing a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, and developing a vaccine for Mpox and smallpox, with plans to proceed directly to a Phase 3 clinical trial.
This update is significant as it provides insights into GeoVax's financial health and progress in developing critical vaccines and therapies, which could have profound implications for public health and the biotechnology industry. The outcomes of these clinical trials and financial results could influence the company's trajectory and its contributions to addressing unmet medical needs in infectious diseases and oncology.
